Single Nucleotide Polymorphisms in the Wnt and BMP Pathways and Colorectal Cancer Risk in a Spanish Cohort Authors: Ceres Fernández-Rozadilla, Luisa de Castro, Juan Clofent, Alejandro Brea-Fernández, Xavier Bessa, Anna Abulí, Montserrat Andreu, Rodrigo Jover, Rosa Xicola, Xavier Llor, Antoni Castells, Sergi Castellví-Bel, Angel Carracedo, Clara Ruiz-Ponte Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0012673 ABSTRACT Colorectal cancer (CRC) is considered a complex disease, and thus the majority of the genetic susceptibility is thought to lie in the form of low-penetrance variants following a polygenic model of inheritance. Candidate-gene studies have so far been one of the basic approaches taken to identify these susceptibility variants. The consistent involvement of some signaling routes in carcinogenesis provided support for pathway-based studies as a natural strategy to select genes that could potentially harbour new susceptibility loci. We selected two main carcinogenesis-related pathways: Wnt and BMP, in order to screen the implicated genes for new risk variants. We then conducted a case-control association study in 933 CRC cases and 969 controls based on coding and regulatory SNPs. We also included rs4444235 and rs9929218, which did not fulfill our selection criteria but belonged to two genes in the BMP pathway and had consistently been linked to CRC in previous studies. Neither allelic, nor genotypic or haplotypic analyses showed any signs of association between the 37 screened variants and CRC risk. Adjustments for sex and age, and stratified analysis between sporadic and control groups did not yield any positive results either. Despite the relevance of both pathways in the pathogenesis of the disease, and the fact that this is indeed the first study that considers these pathways as a candidate-gene selection approach, our study does not present any evidence of the presence of low-penetrance variants for the selected markers in any of the considered genes in our cohort. INTRODUCTION Colorectal cancer (CRC) is one of the main forms of cancer, being the second most frequent neoplasm in both sexes and one of the most important morbidity causes in the western world [1] . The genetic contribution to CRC has been estimated to be around 35% by extensive twin studies [2] . However, highly penetrant variants, that cause mendelian predisposition syndromes, account only for, at most, 5% of the disease cases [3] . The remaining genetic susceptibility is thought to follow a polygenic model, with an interplay of multiple low-penetrance allelic variants appearing in high frequency in the general population, and each conferring a modest effect on disease risk [4] , [5] . Candidate-gene studies have been one of the most commonly used tools in the screening for new variants affecting CRC risk. Gene selection in these studies is mainly based on the functional implications of a possible association, and thus genes selected have either been chosen because of the previous presence of other high/low risk alleles [6] , or their participation in a pathway implicated in the pathogenesis of the disease [7] . Candidate-gene studies can be performed by either direct approaches, where the variants genotyped are presumed to be the underlying cause of the disease because of their location (variants in exonic or regulatory regions), or by indirect approaches, where tag SNPs take advantage of the linkage disequilibrium properties of the human genome to try and screen the most of the variability in a given gene. This latter approach has also allowed, together with the development of high-throughput technologies, the implementation of new hypothesis-free approaches (in opposition with hypothesis-based candidate-gene approaches), covering the majority of the genome (genome-wide association studies or GWAS). This implementation has successfully led to the identification of some new susceptibility loci [8] – [14] , including rs4444235 and rs9929218, that fall within reach of two genes belonging to the BMP pathway. Nevertheless, these have been found to predict only a small proportion of the disease susceptibility, with the remaining yet to be discovered [15] . We hence aimed to find such susceptibility variants through a candidate-gene approach screening a selected number of variants within two cellular pathways that have consistently been linked to CRC tumorogenesis: the Wnt and the BMP signaling pathways [16] , [17] . The Wnt pathway contains genes that have for long been known to be responsible of some hereditary CRC syndromes, such as APC and familial adenomatous polyposis [18] . Moreover, somatic alterations in APC are found in almost 80% of the sporadic colorectal cancers, and Wnt signaling activation is involved in the best part of sporadic colorectal carcinomas [19] . On the other hand, the BMP pathway acts as positive regulator of some of the Wnt proteins [17] , and the tumor suppressive role of this signaling pathway in the pathogenesis of CRC and other cancers is well established [20] , [21] . Besides, mutations in two of its genes, SMAD4 and BMPR1A , are responsible for juvenile polyposis syndrome, another hereditary CRC condition [22] . Considering all this information, we thought it would be interesting to screen some of the genetic variability within these pathways for any evidence of new CRC related variants that could explain at least part of the missing heritability. Our approach was mainly functional, for only SNPs within exonic or cis -regulatory sequences (5′ and 3′ unstranslated regions) were selected to analyse their relationship with CRC susceptibility. RESULTS AND DISCUSSION Following our pathway-based candidate-gene selection method, we performed our study in a total of 45 SNPs that were in either exonic or regulatory regions, in an overall of 21 genes from both the Wnt and BMP pathways. Details of SNP features and association values for the 37 SNPs that successfully passed quality control criteria are shown on Table 1 . None of the screened SNPs were significantly associated with an altered risk of CRC, considering odds-ratios and related p values for allelic and genotypic tests (trend, dominant and recessive). Logistic regression for age and sex adjustment was performed, although it did not improve p value results. Haplotype analysis results were consistent in both Unphased and Haploview, and did not show any signs of positive associations either for any of the 8 genes for which this analysis was performed ( AXIN1 , HDAC9 , BMP4 , DACT1 , CDH3 , CDH1 , BTRC , and APC) , ( Figure S1 ). Stratification analysis comparing sporadic and familial cases was also implemented, but it did not provide any evidence of differences in susceptibilities between the groups that could be a sign of any specific associations within either of the groups ( Table 2 ). Minor allele is depicted in bold. MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval. GT counts. Genotype counts. * Described OR (95%CI) for rs4444235 and rs9929218 were 1.11 (1.08–1.15) and 0.91 (0.89–0.94), respectively, as taken from Houlston et al.. Nat Genet 2008 . MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval. Thus, our strategy has not managed to detect any new susceptibility loci for CRC risk. Pathway-based expectations have proved to be quite discouraging in the literature as well, for strong candidate pathways, such as DNA-repair ones, surprisingly failed too in identifying any new risk variants [7] , [23] – [24] . In addition to this, most of the genetic variants that have been found to be associated with disease are located in intergenic regions, with potential functions that are yet unknown. Still, in light of the recent discoveries that followed up the analysis of genome-wide data, both Wnt and BMP have earned a renewed fame. The susceptibility locus found on 8q24 (rs6983267) has been linked to an enhanced Wnt signaling through its interaction with TCF4 [25] , [26] , and a meta-analysis conducted on a series of GWAS data succeeded in associating two variants in the BMP4 and CDH1 gene regions with the disease (rs4444235 and rs9929218, respectively) [8] . Even though this is actually the first association study that considers the pathways as a whole for gene selection, some of the genes included in our analysis (i.e APC, CCND1 , CDH1 and TCF7 ) had already been screened for risk alleles [6] , [27] – [30] . It is quite remarkable that there has been a growing debate over some of these loci, specially the p.V1822D variant in APC (rs459552). This missense change is widely documented in the literature, with some studies defending it as neutral (this study and others) [31] , and some conferring its minor allele a protective effect [6] , [28] . Lack of appropriate study power, resultant from insufficient number of samples has been a major problem in many of these studies and thus most of them have not provided very convincing results [32] . Although our study had over 80% power to detect OR as low as 1.21 with minor allele frequencies of 0.30 (57% of our SNPs), and 1.24 for MAFs down to 0.2 (78% of the SNPs), assuming a log-additive model and α = 0.05, we were unable to detect any positive associations suggesting the presence of any new CRC susceptibility variants. Nevertheless, it is quite remarkable that, albeit our failure to replicate the associations for the BMP4 and CDH1 SNPs, this is the first study that investigates any of the so-called 10 new GWAS-discovered susceptibility loci in a Southern-European population. Despite our negative results, we must consider that we did not whatsoever comprehensively cover all possible low-penetrance variants within the selected genes. This is mainly due to the fact that our strategy was purely functional, selecting the variants that were a priori good candidates to be directly associated with the disease. This indeed may constitute a limitation in the study, for most of the genetic variation within the loci was not investigated. Thus, we believe further efforts should be made to screen a wider variety of loci within these pathways, specially considering the previous positive associations described so far for both Wnt and BMP-related genes. Pondering the potential odds ratios of the variants described so far (1.11, CI 1.08–1.15 and 0.91, CI 0.89–0.94 for rs4444235 and rs9929218, respectively), we assume larger cohorts may be required to detect such subtle effects. On the other hand, when considering candidate-gene approaches, it would also be useful to meta-analyse previous studies and pull the information across of them altogether in the search of evidences of potential new pathways linked to the pathogenesis of the disease. TABLE: Description of the 37 SNPs that passed quality control criteria and their associated p values. Gene SNP ID SNP type Amino acid change Allele MAF cases MAF controls GT counts cases GT counts controls p-value OR (95% CI) ADAR rs2229857 Missense K384R A /G 0.3306 0.3201 99/360/385 88/347/382 0.512 1.05 (0.91–1.22) APC rs2229992 Synonymous Y486Y C/ T 0.3981 0.4125 145/382/317 141/392/284 0.3728 0.94 (0.82–1.08) APC rs351771 Synonymous A545A C /T 0.3817 0.375 124/397/324 125/416/347 0.7978 1.02 (0.89–1.18) APC rs41115 Synonymous T1493T C /T 0.3796 0.3761 126/385/328 127/414/347 0.8595 1.00 (0.88–1.16) APC rs42427 Synonymous G1678G A/ G 0.3741 0.3713 124/382/336 116/365/323 0.9252 1.01 (0.88–1.17) APC rs459552 Missense V1822D A /T 0.2302 0.2134 48/293/504 41/297/550 0.2197 1.11 (0.94–1.30) APC rs465899 Synonymous P1960P C /T 0.3828 0.3743 126/395/324 125/414/348 0.7107 1.03 (0.90–1.19) APC rs866006 Synonymous S1756S A /C 0.3775 0.3756 123/370/323 124/401/339 0.925 1.00 (0.87–1.19) AXIN1 rs1805105 Synonymous D254D C/ T 0.3918 0.4096 136/387/318 164/397/324 0.2692 0.93 (0.81–1.07) AXIN1 rs214250 Synonymous S428S C/ T 0.2206 0.2028 32/307/502 34/265/522 0.2138 1.12 (0.94–1.32) AXIN1 rs214252 Synonymous A609A A/ G 0.2207 0.2005 32/305/499 34/258/521 0.1403 1.13 (0.96–1.34) AXIN1 rs400037 Missense R388Q C/ T 0.1826 0.1829 27/244/545 39/234/580 0.8972 1.04 (0.87–1.24) AXIN2 rs2240308 Missense P50S A /G 0.4502 0.4219 168/423/252 152/442/290 0.1031 1.11 (0.97–1.27) BMP4 rs17563 Missense V152A C/ T 0.4946 0.4855 211/407/220 208/420/233 0.5498 1.07 (0.93–1.23) BMP4 rs4444235 – – C/ T 0.4563 0.4557 168/436/242 196/411/274 0.9343 0.99 (0.86–1.14) * BTRC rs17767748 Synonymous I229I C/ T 0.05516 0.056 3/86/745 4/91/789 0.9324 1.00 (0.74–1.36) BTRC rs4151060 Missense A543S G/ T 0.04793 0.04904 4/73/768 2/83/802 0.6997 0.96 (0.70–1.32) CCND1 rs603965 Synonymous P241P A /G 0.4969 0.4822 204/406/209 206/430/237 0.4164 1.06 (0.93–1.22) CDH1 rs1801552 Synonymous A692A C/ T 0.3547 0.3781 105/371/343 126/365/325 0.1834 0.92 (0.81–1.07) CDH1 rs9929218 Intronic – A /G 0.2811 0.2873 65/345/435 83/342/459 0.5486 0.97 (0.83–1.13) * CDH3 rs1126933 Missense Q563H C /G 0.3828 0.3802 129/382/325 129/361/324 0.8369 1.02 (0.88–1.17) CDH3 rs17715450 Synonymous R747R A/ C 0.3783 0.3959 116/390/316 147/402/330 0.2792 0.93 (0.80–1.07) CDH3 rs2274239 Synonymous K652K C /T 0.3599 0.3771 108/390/344 126/368/328 0.2863 0.93 (0.81–1.07) CDH3 rs2296408 Synonymous T271T G /T 0.3698 0.3724 107/394/321 130/388/352 0.8768 1.00 (0.87–1.15) CDH3 rs2296409 Synonymous T240T C /T 0.3585 0.3643 106/391/344 130/387/371 0.7962 0.98 (0.85–1.13) CDH3 rs8049247 Synonymous I204I A /C 0.1665 0.1682 21/238/582 22/249/600 0.8683 0.97 (0.81–1.17) DACT1 rs17832998 Missense A464V C/ T 0.3468 0.3448 111/362/369 116/381/392 0.9293 1.01 (0.88–1.17) DACT1 rs863091 Synonymous V378V C/ T 0.2047 0.2033 30/283/525 41/249/524 0.932 1.01 (0.85–1.19) HDAC9 rs1178127 Missense P621P A/ G 0.21 0.2203 37/273/516 41/300/526 0.4737 0.94 (0.80–1.12) HDAC9 rs34096894 Synonymous L152L C/ T 0.01953 0.01351 0/33/812 1/22/865 0.2075 1.33 (0.78–2.27) NLK rs3182380 Synonymous I498I C/ T 0.05142 0.05535 2/83/761 3/85/734 0.4686 0.92 (0.68–1.24) PPARD rs2076167 Synonymous N163N A/ G 0.2956 0.294 72/355/417 78/328/417 0.9891 1.00 (0.86–1.16) SMURF1 rs219797 Synonymous S166S C/ G 0.4452 0.4712 160/428/252 210/415/261 0.1591 0.90 (0.78–1.03) TCF7 rs30489 Missense G256R C/ T 0.07683 0.07937 6/118/722 6/128/748 0.7655 0.97 (0.75–1.25) TLE1 rs2228173 Synonymous E118E A /G 0.1183 0.1172 11/178/656 6/196/685 0.992 1.02 (0.82–1.26) WIF1 rs7301320 Synonymous A73A C/ T 0.2237 0.2219 48/265/494 47/281/517 0.9768 1.00 (0.84–1.18) WNT2B rs910697 Synonymous Q390Q A/ G 0.4218 0.4301 154/404/286 172/419/296 0.5463 0.95 (0.83–1.09) TABLE: Association values for stratified analysis in familial and sporadic CRC groups. Familial vs control Sporadic vs control Familial vs sporadic ADAR rs2229857 0.08586 1.28 (0.97–1.68) 0.8662 1.01 (0.87–1.18) 0.1011 1.26 (0.95–1.67) APC rs2229992 0.6564 1.06 (0.81–1.39) 0.2732 0.92 (0.80–1.07) 0.3214 1.15 (0.87–1.51) APC rs351771 0.3266 1.15 (0.87–1.50) 0.8956 1.01 (0.87–1.17) 0.3659 1.14 (0.86–1.49) APC rs41115 0.4254 1.12 (0.85–1.47) 0.9802 1.00 (0.86–1.15) 0.4306 1.12 (0.85–1.47) APC rs42427 0.3978 1.13 (0.86–1.48) 0.9322 0.99 (0.86–1.15) 0.3825 1.13 (0.86–1.49) APC rs459552 0.05147 1.35 (1.00–1.83) 0.4821 1.06 (0.90–1.26) 0.1313 1.27 (0.93–1.72) APC rs465899 0.3161 1.15 (0.88–1.51) 0.8003 1.02 (0.88–1.18) 0.3885 1.13 (0.86–1.49) APC rs866006 0.3634 1.14 (0.86–1.49) 0.8589 0.99 (0.85–1.14) 0.3256 1.15 (0.87–1.52) AXIN1 rs1805105 0.0674 0.77 (0.58–1.02) 0.5492 0.96 (0.83–1.10) 0.1524 0.81 (0.61–1.08) AXIN1 rs214250 0.5041 1.12 (0.81–1.55) 0.2312 1.11 (0.93–1.32) 0.9975 1.00 (0.72–1.39) AXIN1 rs214252 0.4511 1.13 (0.82–1.57) 0.1736 1.13 (0.95–1.34) 0.9984 1.00 (0.72–1.39) AXIN1 rs400037 0.1971 1.25 (0.89–1.74) 0.6545 0.96 (0.80–1.15) 0.1447 1.29 (0.92–1.81) AXIN2 rs2240308 0.7901 1.04 (0.78–1.36) 0.0733 1.14 (0.99–1.31) 0.5069 0.91 (0.69–1.20) BMP4 rs17563 0.1037 1.25(0.95–1.64) 0.9434 1.01 (0.87–1.16) 0.1119 1.25 (0.95–1.64) BMP4 rs4444235 0.2311 0.85 (0.65–1.11) 0.6689 1.03 (0.90–1.19) 0.1486 0.82 (0.62–1.08) BTRC rs17767748 0.7285 1.10 (0.63–1.93) 0.813 0.96 (0.71–1.31) 0.6361 1.15 (0.65–2.03) BTRC rs4151060 0.1176 1.52 (0.90–2.57) 0.4741 0.89 (0.64–1.24) 0.04729 1.72 (1.00–2.96) CCND1 rs603965 0.335 0.87 (0.66–1.15) 0.2045 1.10 (0.95–1.26) 0.1203 0.80 (0.61–1.06) CDH1 rs1801552 0.6563 1.07 (0.80–1.41) 0.08919 0.88 (0.76–1.02) 0.1812 1.21 (0.91–1.61) CDH1 rs9929218 0.8686 0.98 (0.73–1.31) 0.6861 0.97 (0.83–1.13) 0.926 1.01 (0.75–1.37) CDH3 rs1126933 0.1283 1.23 (0.94–1.62) 0.7438 0.98 (0.84–1.13) 0.09059 1.27 (0.96–1.67 CDH3 rs17715450 0.2767 0.86 (0.65–1.13) 0.4126 0.94 (0.82–1.09) 0.5064 0.91 (0.68–1.21) CDH3 rs2274239 0.1972 0.83 (0.63–1.10) 0.4589 0.95 (0.82–1.10) 0.3649 0.88 (0.66–1.17) CDH3 rs2296408 0.4447 0.90 (0.68–1.19) 0.9386 1.01 (0.87–1.16) 0.4216 0.89 (0.67–1.18) CDH3 rs2296409 0.1256 0.80 (0.60–1.07) 0.9158 1.01 (0.87–1.17) 0.1138 0.79 (0.59–1.06) CDH3 rs8049247 0.9636 1.01 (0.71–1.44) 0.867 0.98 (0.82–1.19) 0.9021 1.02 (0.71–1.47) DACT1 rs17832998 0.9185 0.99 (0.74–1.31) 0.8619 1.01 (0.88–1.17) 0.8392 0.97 (0.73–1.29) DACT1 rs863091 0.5683 0.90 (0.64–1.28) 0.7737 1.03 (0.86–1.22) 0.4595 0.88 (0.62–1.24) Gene SNP ID p-value OR (CI 95%) p-value OR (CI 95%) p-value OR (CI 95%) HDAC9 rs1178127 0.8693 1.03 (0.74–1.42) 0.3847 0.93 (0.78–1.10) 0.5511 1.11 (0.80–1.54) HDAC9 rs34096894 0.8555 0.89 (0.27–2.99) 0.1093 1.55 (0.90–2.67) 0.3638 0.58 (0.18–1.91) NLK rs3182380 0.4747 0.79 (0.42–1.50) 0.7387 0.95 (0.69–1.30) 0.5917 0.84 (0.44–1.60 PPARD rs2076167 0.1051 0.77 (0.57–1.06) 0.5291 1.05 (0.90–1.23) 0.06342 0.74 (0.55–1.02) SMURF1 rs219797 0.9123 0.99 (0.75–1.29) 0.09224 0.89 (0.77–1.02) 0.4764 1.10 (0.84–1.45) TCF7 rs30489 0.1722 1.36 (0.87–2.11) 0.4351 0.90 (0.69–1.17) 0.07095 1.51 (0.96–2.38) TLE rs2228173 0.4715 1.16 (0.78–1.71) 0.8995 0.99 (0.79–1.23) 0.4626 1.16 (0.78–1.73) WIF1 rs7301320 0.2681 1.20 (0.87–1.64) 0.8226 0.98 (0.83–1.16) 0.2418 1.21 (0.88–1.67) WNT2B rs910697 0.4228 0.90 (0.68–1.17) 0.7713 0.98 (0.85–1.13) 0.5418 0.92 (0.70–1.21) MATERIALS AND METHODS Subjects were 933 CRC patients and 969 controls that belonged to the EPICOLON project, a prospective, multicentre, population-based epidemiology survey studying the incidence and features of familial and sporadic CRC in the Spanish population [33] . Cases were selected across 11 hospitals in Spain as all patients with a de-novo histologically confirmed diagnosis of colorectal adenocarcinoma and who attended 11 community hospitals across Spain between November 2006 and December 2007. Patients in whom CRC developed in the context of familial adenomatous polyposis or inflammatory bowel disease, and cases where patients or family refused to participate in the study were excluded. Demographic, clinical and tumour-related characteristics of probands, as well as a detailed family history were obtained using a pre-established questionnaire, and registered in a single database. Of these, 592 (63%) were male and 341 (37%) female. Median age for cases was 73 (range 26–95), whereas mean was 71(SD±10.7). Hospital-based controls were recruited together with cases and were confirmed to have no cancer or prior history of neoplasm, and no family history of CRC. All controls were randomly selected and matched with cases for sex and age (±5 years) in a 1∶1 ratio. Both cases and controls were of European ancestry and from Spain. ETHICS STATEMENT The study was approved by the “Comité Ético de Investigación Clínica de Galicia”, and each of the institutional review boards of the hospitals where samples were collected (“Ethics Committee of the Hospital Clínic-Barcelona”, “Ethics Committee of the Hospital del Mar-Barcelona”, “Ethics Committee of the Hospital German Trias i Pujol-Barcelona”, “Ethics Committee of the Hospital Sant Pau-Barcelona,” “Ethics Committee of the Hospital Universitari Arnau de Vilanova-Lleida”, “Ethics Committee of the Hospital General-Alicante”, “Ethics Committee of the Hospital de Donosti”, “Ethics Committee of the Hospital General de Asturias-Oviedo”, “Ethics Committee of the Hospital Clinico-Zaragoza”, “Ethics Committee of the Hospital de Calahorra-La Rioja”, “Ethics Committee of the Hospital Meixoeiro-Vigo”). All samples were obtained with written informed consent reviewed by the ethical board of the corresponding hospital. DNA EXTRACTION DNA was obtained from frozen peripheral blood; extraction was performed in a CHEMAGEN robot (Chemagen Biopolymer-Technologie AG, Baesweiler, Germany) in accordance with the manufacturer's instructions, at the Galician Public Fundation of Genomic Medicine in Santiago de Compostela. Cases and controls were extracted in mixed batches to avoid any kind of bias. CANDIDATE-GENE SELECTION Both Wnt and BMP pathways were initially selected after the findings of Nishanian et al. [34] , who demonstrated the interaction between these two pathways. Both pathways were thoroughly investigated through the Cancer Genome Anatomy Project site [35] , but we failed to find any information regarding the BMP pathway in either this or other web browsers. For that reason, Wnt genes were selected by browsing the pathway through Biocarta [36] , whereas BMP genes had to be strictly selected from previous literature [17] , [34] . Forty-one genes were finally selected to be included in the analysis. SNP SELECTION AND GENOTYPING SNP selection criteria only considered functional markers with minor allele frequencies above 0.05 and at least two independent validation criteria as established in dbSNP [37] . This included all exonic variants selected with Pupasuite [38] and gene-regulatory regions in cis (5′or 3′ UTR ends), as defined by the FESD web browser [39] . 5′UTR variants were only included when they complied to the abovementioned criteria and were presumed to be in the potential binding site of a known transctiptional binding factor. 3′ UTR variants were included because of their potential relationship with miRNA binding regions [40] . Because some of the selected genes had no SNPs of such these kinds in any of the three browsers at the time of SNP selection, they ultimately had to be dropped out of the study. Finally, 43 SNPs were chosen within 21 genes to be screened as potential direct modifiers of CRC susceptibility ( Table 3 ). Genes finally screened are depicted in bold. NA denotes not available SNPs for a given gene considering our selection criteria. rs4444235 and rs9929218 are not shown, for they were included because of their previous associations and not because they fulfilled our functional criteria. rs4444235 and rs9929218 are two variants lying in the near-by and intronic regions of BMP4 and CDH1 , respectively, that have been recently reported to be associated with the disease [8] . Considering that the SNPs that we had chosen within these two genes were not good taggers for these two variants (r-squared values were 0.6 for the SNPs in BMP4 , and 0.02 for those in CHD1 ) ( Figure 1 ), we decided to include them in our study as well, although they did not fulfill our selection criteria, making the total number of interrogated SNPs rise to 45. R-squared relationships between SNP pairs: A. rs4444235-rs17563 in BMP4 and B. rs9929218-rs1801552 in CDH1 . Genotyping was performed with the MassARRAY (Sequenom Inc., San Diego, USA) technology at the Santiago de Compostela node of the Spanish Genotyping Center. Calling of genotypes was done with Sequenom Typer v4.0 software using all the data from the study simultaneously. TABLE: Description of all genes selected from both pathways and SNPs screened within each of them. Gene Name Function pathway/genes modulated by BMP signalling SNPs selected ADAR, Adenosine deaminase, RNA- specific Converts multiple adenosines to inosines and creates I/U mismatched base pairs in double-helical RNA Wnt signalling 36 rs2229857 APC, Adenomatous Polyposis Coli B-catenin degradation Wnt signalling 36 rs2229992,rs351771,rs4115,rs42427rs459552,rs465899,rs86006 AXIN1 , Axin 1 B-catenin regulation Wnt signalling 36 rs1048786,rs1805105,rs214250,rs214252,rs400037,rs419949 BTRC , Beta-transducin repeat containing B-catenin ubiquitination Wnt signalling 36 rs17767748,rs415060 CCND1 , Cyclin D1 Cell cycle control Wnt signalling 36 rs603965 CSNK1A1 , Casein kinase 1, alpha 1 B-catenin fosforilation Wnt signalling 36 NA CSNK2A1 , Casein kinase 2, alpha 1 B-catenin fosforilation Wnt signalling 36 NA CTBP1 , C-terminal binding protein 1 Transcriptional repressor in cellular proliferation Wnt signalling 36 NA CTNNB1 , Catenin (cadherin-associated protein), beta 1 Cell adhesion and signal transduction Wnt signalling 36 NA EIF4E , Eukaryotic translation initiation factor 4E Translation initiation factor Wnt signalling 36 NA ELAC1 , ElaC homolog 1 (E. coli) Zinc phosphodiesterase Wnt signalling 36 NA FRAT1 , Frequently rearranged in advanced T-cell lymphomas B-catenin stabilization Wnt signalling 36 NA FZD1 , Frizzled homolog 1 (Drosophila) Receptor for Wnt proteins Wnt signalling 36 NA GSK3B , Glycogen synthase kinase 3 beta B-catenin fosforilation Wnt signalling 36 rs34002644 HDAC9 , Histone deacetylase 9 Transcriptional regulation, cell cycle Wnt signalling 36 rs1178127,rs34096894 HNF4A , Hepatocyte nuclear factor 4, alpha Transcriptionally controlled transcription factor Wnt signalling 36 rs35078168 MAP3K7 , Mitogen-activated protein kinase kinase kinase 7 Signaling transduction induced by BMP Wnt signalling 36 NA MYC , v-myc myelocytomatosis viral oncogene homolog (avian) Regulation of gene transcription Wnt signalling 36 NA NLK , Nemo-like kinase Negatively regulation wnt pathway Wnt signalling 36 rs3182380 PPARD , Peroxisome proliferator-activated receptor delta Ligand-activated transcription factor. Wnt signalling 36 rs2076167 PPP2R4, Protein phosphatase 2A activator, regulatory subunit 4 Folding of proteins Wnt signalling 36 NA TLE1 , Transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) Transcriptional corepressor Wnt signalling 36 rs2228173,rs8782 WIF1 , Wnt inhibitory factor 1 Inhibition of the WNT activities Wnt signalling 36 rs1026024,rs7301320 WNT1 , Wingless-type MMTV integration site family, member 1 Ligand for members of the frizzled family Wnt signalling 36 NA BMP4 , Bone morphogenetic protein 4 Induces cartilage and bone formation. BMP signalling 17 rs17563 BMPR1B , Bone morphogenetic protein receptor, type IB Transmembrane serine/threonine BMP signalling 17 NA SMAD1 , SMAD family member 1 Signal transduction BMP signalling 17 NA SMAD4 , SMAD family member 4 Signal transduction BMP signalling 17 rs75667697 SMAD5 , SMAD family member 5 Signal transduction BMP signalling 17 NA SMURF1 , SMAD specific E3 ubiquitin protein ligase 1 Ubiquitination and degradation of SMAD proteins BMP signalling 17 rs219797 AXIN2 , Axin 2 B-catenin regulation Wnt signalling, BMP induced genes 34 rs2240308 CDH1 , Cadherin 1, type 1, E-cadherin B-catenin regulation Wnt signalling, BMP induced genes 34 rs1801552 CDH3 , Cadherin 3, type 1, P-cadherin (placental) B-catenin regulation Wnt signalling, BMP induced genes 34 rs1126933,rs17715450,rs2274239,rs2296408,rs2296409,rs8049247 DAB2 , Disabled homolog 2, mitogen-responsive phosphoprotein B-catenin regulation Wnt signalling, BMP induced genes 34 NA DACT1 , Dapper antagonist of beta-catenin, homolog 1 (Xenopus laevis) Disheveled inhibitor Wnt signalling, BMP induced genes 34 rs17832998,rs698025,rs863091 KIFAP3 , Kinesin-associated protein 3 Interacts with apc Wnt signalling, BMP induced genes 34 NA LEF1 , Lymphoid enhancer-binding factor 1 Transcriptional activator of Wnt signaling Wnt signalling, BMP induced genes 34 NA TCF7 , Transcription factor 7 (T-cell specific, HMG-box) transcriptional repressor of CTNNB1 Wnt signalling, BMP induced genes 34 rs30489 WNT2B , Wingless-type MMTV integration site family, member 2B Wnt ligand Wnt signalling, BMP induced genes 34 rs910697 WNT5A , Wingless-type MMTV integration site family, member 5A Wnt ligand Wnt signalling, BMP induced genes 34 NA WNT5B , Wingless-type MMTV integration site family, member 5B Wnt ligand Wnt signalling, BMP induced genes 34 NA STATISTICAL ANALYSES Quality control was performed, first by excluding both SNPs and samples with genotype success rates below 95%, with the help of the Genotyping Data Filter (GDF) [41] . Genotypic distributions for all SNPs in controls were consistent with Hardy-Weinberg equilibrium as assessed using a X 2 test (1 df ). All p-values obtained were ≥0.05, thereby excluding the possibility of genotyping artifacts (data not shown). Population stratification was assessed with Structure v2.2 [42] . Briefly, the posibility of different scenarios was tested assuming a different number of underlying populations (k ranging from 1 to 4), allowing for a large number of iterations (25 K in the burn-in period followed by 500 K repetitions). The mean log likelihood was estimated for the data for a given k (referred to as L(K)) in each run. We as well performed multiple runs for each value of k computing the overall mean L(K) and its standard deviation. All results seemed to be concordant with the original assumption of a single existing population. Moreover, additional procedures for better confounding variable visualization were undertaken by means of a Principal Component Analysis (PCA) using the EIGENSOFT tool smartpca [43] , although number of markers was very low. No differences were found of population stratification between cases and controls for either STRUCTURE or the first 10 components of the PCA analysis ( Figure S2 ). After quality control 1746 samples (854 cases and 892 controls) and 37 SNPs remained for further analyses. Association tests were performed by chi-squared tests for every single SNP and haplotypes where possible with both Haploview v4.0 [44] and Unphased [45] . In short, LD patterns across genes for which more than one SNP was genotyped were checked in Haploview and tested for association using Unphased (to check in any of the haplotypes was associated) and Haploview (to see which of the haplotypes was associated). Genotypic association tests, logistic regression analysis for sex and age adjustment, and stratified analysis between sporadic and familial groups were estimated with PLINK v1.03 [46] . OR and 95% confidence intervals were calculated for each statistic, and to address the issue of multiple-testing, permutation tests and the Bonferroni correction were used. Study power was estimated with CATS software [47] . SUPPORTING INFORMATION Haplotype structure and analysis for the 8 genes for which more than one SNP was genotyped. The table shows association values for each SNP generated by Haploview. (3.40 MB TIF) Principal component analysis plot for the first vs. second component, comparing our case and control populations. (0.96 MB TIF) (0.03 MB DOC) REFERENCES [1] Ferlay J Bray F Pisani P Parkin DM 2004 GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base No. 5. version 2.0. [2] Lichtenstein P Holm NV Verkasalo PK Iliadou A Kaprio J 2000 Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 78 85 [3] de la Chapelle A 2004 Genetic predisposition to colorectal cancer. Nat Rev Cancer 4 769 80 [4] Castells A Castellví-Bel S Balaguer F 2009 Concepts in familial colorectal cancer: where do we stand and what is the future? Gastroenterology 137 404 409 [5] Houlston RS Peto J 2004 The search for low-penetrance cancer susceptibility alleles. Oncogene 23 6471 6 [6] Chen SP Tsai ST Jao SW Huang YL Chao YC 2006 Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan. BMC Cancer 6 83 [7] Naccarati A Pardini B Hemminki K Vodicka P 2007 Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res 635 118 45 [8] Houlston RS Webb E Broderick P Pittman AM Di Bernardo MC 2008 Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 40 1426 35 [9] Tomlinson I Webb E Carvajal-Carmona L Broderick P Kemp Z 2007 A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39 984 8 [10] Zanke BW Greenwood CM Rangrej J Kustra R Tenesa A 2007 Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39 989 94 [11] Broderick P Carvajal-Carmona L Pittman AM Webb E Howarth K 2007 A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39 1315 7 [12] Jaeger E Webb E Howarth K Carvajal-Carmona L Rowan A 2008 Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet 40 26 8 [13] Tomlinson IP Webb E Carvajal-Carmona L Broderick P Howarth K 2008 A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 40 5 623 30 [14] Tenesa A Farrington SM Prendergast JG Porteous ME Walker M 2008 Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40 5 631 7 [15] Cazier JB Tomlinson I 2010 General lessons from large-scale studies to identify human cancer predisposition genes. J Pathol 220 2 255 62 [16] Segditsas S Tomlinson I 2006 Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25 7531 7 [17] Huang HC Klein PS 2004 Interactions between BMP and Wnt signaling pathways in mammalian cancers. Cancer Biol Ther 3 676 8 [18] Half E Bercovich D Rozen P 2009 Familial adenomatous polyposis. Orphanet J Rare Dis 4 22 [19] Rowan AJ Lamlum H Ilyas M Wheeler J Straub J 2000 APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc Natl Acad Sci U S A 97 3352 7 [20] Deng H Ravikumar TS Yang WL 2009 Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. Cancer Lett 281 220 31 [21] Deng H Makizumi R Ravikumar TS Dong H Yang W 2007 Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 313 1033 44 [22] Chen HM Fang JY 2009 Genetics of the hamartomatous polyposis syndromes: a molecular review. Int J Colorectal Dis 24 8 865 74 [23] Tao H Shinmura K Suzuki M Kono S Mibu R 2008 Association between genetic polymorphisms of the base excision repair gene MUTYH and increased colorectal cancer risk in a Japanese population. Cancer Sci 99 355 60 [24] Schafmayer C Buch S Egberts JH Franke A Brosch M 2007 Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer. Int J Cancer 121 555 8 [25] Pomerantz MM Ahmadiyeh N Jia L Herman P Verzi MP 2009 The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41 882 4 [26] Tuupanen S Turunen M Lehtonen R Hallikas O Vanharanta S 2009 The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41 885 90 [27] Picelli S Zajac P Zhou XL Edler D Lenander C 2010 Common variants in human CRC genes as low-risk alleles. Eur J Cancer 46 6 1041 8 [28] Slattery ML Samowitz W Ballard L Schaffer D Leppert M 2001 A molecular variant of the APC gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer. Cancer Res 61 1000 4 [29] Liu B Zhang Y Jin M Ni Q Liang X 2010 Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog 49 75 84 [30] Hazra A Fuchs CS Chan AT Giovannucci EL Hunter DJ 2008 Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. Cancer Causes Control 19 975 80 [31] Ruiz-Ponte C Vega A Conde R Barros F Carracedo A 2001 The Asp1822Val variant of the APC gene is a common polymorphism without clinical implications. J Med Genet 38 E33 [32] Kemp Z Thirlwell C Sieber O Silver A Tomlinson I 2004 An update on the genetics of colorectal cancer. Hum Mol Genet 13 Spec No 2 R177 85 [33] Pinol V Castells A Andreu M Castellvi-Bel S Alenda C 2005 Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293 1986 94 [34] Nishanian TG Kim JS Foxworth A Waldman T 2004 Suppression of tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4 in human cancer cells. Cancer Biol Ther 3 667 75 [35] The Cancer Genome Anatomy Project webpage 2006 http://cgap.nci.nih.gov/ [36] Biocarta 2006 http://www.biocarta.com/genes/index.asp [37] 126.dbSNP (accessed 2007). http://www.ncbi.nlm.nih.gov/projects/SNP/ [38] Conde L Vaquerizas JM Dopazo H Arbiza L Reumers J 2006 PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 34 W621 5 [39] Kang HJ Choi KO Kim BD Kim S Kim YJ 2005 FESD: a Functional Element SNPs Database in human. Nucleic Acids Res 33 D518 22 [40] Jackson RJ Standart N 2007 How do microRNAs regulate gene expression? Science 367 re1 [41] Genotyping Data Filter Software 2009 http://bioinformatics.cesga.es/gdf/nav_input.php [42] Pritchard JK Stephens M Donnelly P 2000 Inference of population structure using multilocus genotype data. Genetics 155 945 59 [43] Patterson N Price AL Reich D 2006 Population structure and Eigenanalysis. PLoS Genet 2 12 [44] Barrett JC Fry B Maller J Daly MJ 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 263 5 [45] Dudbridge F 2003 Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25 115 21 [46] Purcell S Neale B Todd-Brown K Thomas L Ferreira MA 2007 PLINK: a toolset for whole-genome association and population-based linkage-analysis. American Journal of Human Genetics 81 559 75 http://pngu.mgh.harvard.edu/~purcell/plink/ [47] Skol AD Scott LJ Abecasis GR Boehnke M 2006 Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38 209 13